JWJiakai Wu

Jiakai Wu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jiakai Wu has a total of 42 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Functional Mast Cell Testing Identifies Clinically Relevant Cat Sensitisation

    by Jiakai Wu, Ran Wang, Gail Gauvreau, Ruth P. Cusack, Silvia Bulfone‐Paus, Clare S. Murray, Angela Simpson

    Summary: MAT correlated with cat‐specific IgE but was not interchangeable and may identify cat‐induced asthma‐like symptoms. MAT correlated with objective airway responses in a combined two‐centre inhaled cat allergen challenge cohort.

  • Open Access

    Basophil Activating Factors in the Serum May Underlie the ‘Nonreleaser’ Basophil Status in the Basophil Activation Test

    by Jiakai Wu, Chiara Tontini, Ran Wang, Silvia Bulfone‐Paus, Clare S. Murray, Angela Simpson


  • Open Access

    Performance characteristics of basophil activations tests for diagnosing penicillin allergy: a meta-analysis

    by Miriam Bennett, Jiakai Wu, Alexander G. Mathioudakis, Chiara Tontini, Iason Thomas, Angela Simpson

    Background: Approximately 10% of the global population identify themselves as penicillin allergic, yet 90% are not truly allergic and could safely tolerate penicillin. There is no simple way to identify these people. Current in vitro diagnostics include specific immunoglobulin E, sIgE (with a sensitivity of 19% and specificity of 97%) and basophil activation testing (BAT) with undefined sensitivity and specificity. Objective: To define the sensitivity and specificity of BAT in the diagnosis of penicillin allergy Methods: PubMed and EMBASE searched from inception to 04/02/2023 for original studies evaluating the performance characteristics of basophil activation test for penicillin allergy in adults. Study selection, data extraction, risk of bias, assessment with QUADAS-2 tool, certainty assessment with GRADE methodology were performed independently, in duplicate. Meta-analysis was performed using Reitsma methodology. Results: Twenty-two studies fulfilled the inclusion criteria. Twelve used the same positive threshold giving a summary point sensitivity 51% (95% CI, 46%-56%) and specificity 89% (95% CI, 85%-93%). Significant risk of bias was identified due to patient selection. GRADE certainty of evidence rated sensitivity “very low” due to imprecision and specificity as “low”. There was great heterogeneity in methods used. Use of 1000 basophils per test did not improve performance above 500 basophils. Conclusion: BAT sensitivity is highly variable across studies and remains too low to be considered as a routine element of clinical practice. BAT specificity is not as good as sIgE in penicillin allergy diagnosis. Significant further work is required in this field before clinical application of BAT in routine practice.

  • Open Access

    Amoxicillin induced mast cell degranulation mediated by FcεRI specific IgG: a new insight to beta-lactam allergy

    by Jiakai Wu, Miriam Bennett, Silvia Bulfone-Paus, Sara Kirkham, Clare Murray, Angela Simpson

    Amoxicillin induced mast cell degranulation mediated by FcεRI specific IgG: a new insight to beta-lactam allergy To the editor,Immediate drug hypersensitivity reactions (IDHR) to beta-lactams (BL), referred to here as beta-lactam allergy (BLA), is defined as the development of symptoms such as urticaria and bronchospasm within one hour of beta-lactam exposure (1). Classical Type 1 immunoglobulin E (IgE)-mediated allergy describes a response which occurs within minutes of allergen exposure in a previously sensitised person. It has therefore been widely accepted that BLA is mediated by beta-lactam specific IgE (BL-sIgE) (1). In other Type 1 IgE driven allergies, such as food allergy, sIgE to major allergen components can be shown to be highly specific (2, 3). However, for BLA, BL-sIgE has poor specificity, suggesting alternative mechanisms might be involved (4).Type 1 IgE mediated reactions are mainly mediated by basophils and mast cells (MCs). Previous studies have demonstrated the use of the basophil activation test (BAT) in predicting BLA, with European allergy guidance stating that BAT can aid BLA diagnosis (5). However, BAT requires fresh whole blood which is not ideal for in depth mechanistic exploration.In an in vitro BLA model using human progenitor derived MCs, we have shown that MCs sensitised with serum from a patient with confirmed BLA, demonstrated amoxicillin (AMX) induced degranulation (CD63+ positivity) after 30 minutes of stimulation with AMX (Figure 1B). In contrast, sensitisation with serum from a non-BLA control demonstrated no response (Figure 1C).The mechanism of degranulation from the BLA model is very different from the classical IgE-mediated Type 1 degranulation such as that seen in food and inhalant allergy (6). In our in vitro model of classical IgE-mediated Type 1 degranulation, sIgE binds to FcɛRI with high affinity which is not disturbed by pipetting and washing (6). In our BLA model, BLA serum sensitized MCs have a much weaker degranulation and can easily lose their response to beta-lactam stimulation under physical disturbance (Figure 1A).We hypothesised that FcɛRI was involved in the degranulation process in BLA, not through the high affinity binding of IgE, but instead through IgG binding. We produced a recombinant fragment representing the extracellular portion of the FcɛRI receptor alpha chain, which is mainly responsible for antibody binding. When added to the serum, this fragment binds and neutralizes FcɛRI-specific antibody—IgE and IgG, by preventing them binding to the cells. BLA serum was treated with increasing concentrations of the FcɛRI fragments and then added to the MCs for sensitization. After stimulating the sensitized MCs using AMX, we observed a dosage-dependent decrease of MCs degranulation, indicating direct involvement of the FcɛRI in the degranulation process of BLA (Figure 2A).To investigate whether degranulation was mediated by IgE, we neutralized serum IgE by adding omalizumab before MC sensitisation. This showed no impact on the AMX induced degranulation (Figure 2A). In contrast, omalizumab inhibited MC degranulation in a classical IgE model, using pooled serum from cat allergic patients stimulated with cat allergen (Figure 2B).To determine whether FcεRI-specific IgG is functionally responsible for the AMX induced MCs degranulation, we isolated IgG from BLA serum using IgG-depletion spin columns. MCs sensitized with the IgG-only fraction showed no response to anti-IgE, but retained a strong response to AMX (Figure 2B). In comparison, in the IgG-depleted serum fraction (~60% IgG removed), we observed a strong degranulation to anti-IgE stimulation but a weakened response to AMX (Figure 2C).A limitation of this preliminary work is it used serum from only one BLA patient.In summary, we developed a cell model for BLA using in vitrodifferentiated human MCs. This BLA model has demonstrated the involvement of FcεRI-specific IgG in mediating AMX-induced MCs degranulation. The results are worthy of further investigation in a larger patient cohort.Word Count 599Figure legend ( Word count 98 and 98 respectively, max 100)Figure 1. Demonstration of in vitro BLA model using MCs derived from human progenitor cells. A) After washing the sensitized MCs with phosphate buffered saline (PBS), different cells responsiveness to AMX and anti-IgE. B) When adding the AMX in the presence of BL IDHR serum, cell degranulation was observed. C) No degranulation was observed from AMX stimulation when serum from a non-BL IDHR subject was used. D) Treatment of AMX in the absence of serum showed a mild increase of CD63 compared to cells without stimulation, Percentage CD63+ cells is shown in the box. Representative figures from three independent experiments.Figure 2. Investigating the role of FcεRI-specific IgG in BLAin vitro model A) the BLA in vitro model, B) classical type I IgE cat allergy model. AMX or cat allergen induced degranulation was quantified on MCs sensitized with single BLA or pooled cat allergic subject serum pre-treated with recombinant FcεRI alpha chain fragment or omalizumab. C) BLA in vitro model; MCs sensitized with either IgG-depleted serum fraction or IgG-only fraction. Sensitised MCs were stimulated with anti-IgE, AMX or media control. Histogram demonstrating fluorescence intensity of CD63 expression on MCs surface. Mean ±SD. *=p<0.05 from three independent experiments, NS=not significant.


  • Open Access

    Progenitor cell‐derived basophils: A novel barcoded passive degranulation assay in allergic diseases

    by Jiakai Wu, Rajia Bahri, Marina Tsoumani, Aida Semic‐Jusufagic, Clare S. Murray, Adnan Custovic, George V. Guibas, Miriam Bennett, Ran Wang, Gail Gauvreau, et al.

    Background: Effector cells assays provide an overall measure of responsiveness to allergen, but the lack of reliable and high‐throughput assays limits the clinical utility. We aimed to develop a high‐throughput basophil activation test based on human progenitor cell‐derived basophils (PCB) and investigate the role of PCB activation test (PCBAT) in allergic diseases.Methods: Progenitor cell‐derived basophils were differentiated from CD34+ progenitor cells and sensitized with sera from subjects sensitized to cat, peanut or atopic controls. Sensitized PCBs were stimulated with increasing concentrations of the corresponding allergens in vitro. Degranulation was assessed by measuring CD63 expression using flow cytometry. The correlations between PCBAT and clinical allergy were assessed.Results: Following passive sensitization of the mature PCBs with serum and allergen stimulation, an allergen specific dose‐dependent increase in CD63 expression was observed. Sera from subjects sensitized to cat (n = 35, of which 17 subjects had clinical reactivity quantified using inhaled allergen challenge), peanut allergic (n = 30, of which 15 subjects had clinical reactivity validated using double blind, placebo controlled food challenges [DBPCFC]), peanut‐sensitized but tolerant subjects (n = 5) were used to sensitize PCBs. PCBAT area under the curve (AUC) correlated with sIgE (r2 = .49, p = .001) in subjects sensitized to cat (sIgE ≥ 0.35KU/L). The provocation concentration of inhaled cat allergen (PC20) correlated with PCBAT AUC (r2 = .33, p = .016). In subjects sensitized to peanut, PCBAT AUC was highly correlated with sIgE to Ara h 2 (r2 = .59, p < .0001). Peanut threshold cumulative dose during DBPCFC was negatively correlated with PCBAT AUC (r2 = .57, p = .001) and IgE to Ara h1 (r2 = .55, p = .007), but not with sIgE to whole peanut or Ara h2. All peanut‐sensitized but tolerant subjects showed no reaction to peanut on PCBAT.Conclusion: Progenitor cell‐derived basophils activation test is a high‐throughput assay, which correlates with clinical allergy and may confer a powerful alternative tool in allergy testing.


  • Open Access

    Progenitor cell-derived basophils: a novel barcoded passive degranulation assay in allergy diagnosis

    by Jiakai Wu, Rajia Bahri, Marina Tsoumani, Aida Semic-Jusufagic, Clare Murray, A Custovic, George Guibas, Miriam Bennett, Gail Gauvreau, Ruth Cusack, et al.

    Background: Effector cells assays provide an overall measure of responsiveness to allergen, but the lack of reliable, high-throughput assays limits the clinical utility of this approach. The aim of this study was to develop a high-throughput Basophil Activation Test (BAT), based on human progenitor cell-derived basophils (PCB), and to investigate the role of PCB activation test (PCBAT) in allergy diagnosis. Methods: PCBs were differentiated from CD34+ progenitor cells, and sensitized with sera from subjects sensitized to cat (n=35, 17 subjects clinical reactivity validated), peanut-allergic (n=30, 15 subjects clinical reactivity validated), peanut-sensitized but tolerant subjects (n=13). Sensitized PCBs were then stimulated with a range of concentrations of the corresponding allergens and degranulation was measured using CD63 expression on flow cytometry. Results: Following passive sensitisation of the mature PCB (2D7+/FcεRI+/CD117-/HLADR-) with serum and stimulation with allergen, we saw a dose-dependent increase in CD63 expression which was allergen specific. In subjects sensititsed to cat there was a positive correlation between PCBAT area under curve (AUC) versus specific IgE (sIgE) to cat (p=0.001) and versus airway responsiveness to inhaled cat allergen (p=0.026). There was a significant negative correlation between PCBAT AUC for peanut allergen and response to oral food challenge test to peanut - subjects with higher PCBAT AUC reacted to a lower dose on the oral food challenge to peanut (p=0.001), and had higher sIgE to Ara h 1 (p=0.007). All peanut tolerant subjects showed no reaction to peanut on PCBAT. Conclusion: PCBAT may confer a powerful alternative tool in allergy testing.

  • Open Access

    Mast cell activation test in the diagnosis of allergic disease and anaphylaxis

    by Rajia Bahri, Adnan Custovic, Peter Korosec, Marina Tsoumani, Martin Barron, Jiakai Wu, Rebekah Sayers, Alf Weimann, Monica Ruiz-Garcia, Nandinee Patel, et al.


  • Open Access

    Relationship between cytokine expression patterns and clinical outcomes: two population‐based birth cohorts

    by Jiakai Wu, Mattia C.F. Prosperi, Angela Simpson, Elysia M Hollams, Peter D Sly, Adnan Custovic, Patrick G Holt

    Summary: Background: Models that incorporate patterns of multiple cytokine responses to allergens, rather than individual cytokine production, may better predict sensitization and asthma.Objective: To characterize the patterns of peripheral blood mononuclear cells’ (PBMCs) cytokine responses to house dust mite (HDM) allergens among children from two population‐based birth cohorts using machine learning techniques.Methods: PBMCs collected at 8 years of age from the UK Manchester Asthma and Allergy Study (n = 268) and at 14 years of age from the Australian Raine Study (n = 1374) were cultured with HDM extract (10 μg/ml). Cytokine expression (IL‐13, IL‐5, IFN‐γ, and IL10) was measured in the supernatant. Cytokine patterns were identified using a Gaussian mixture model clustering, and classification stability was assessed by bootstrapping.Results: A six‐class model indicated complex latent structure of cytokine expression. Based on the characteristics of each class, we designated them as follows: ‘Nonresponders’ (n = 905, 55%); ‘IL‐10 responders’ (n = 49, 3%); ‘IFN‐γ and IL‐13 medium responders’ (n = 56, 3.4%); ‘IL‐13 medium responders’ (n = 351, 21.4%); ‘IL‐5 and IL‐13 medium responders’ (n = 77, 4.7%); and ‘IL‐13 and IL‐5 high responders’ (n = 204, 12.4%). ‘IL‐13 and IL‐5 high responders’ were at much higher risk of HDM sensitization and asthma compared to all other classes, with 88% of children assigned to this class being sensitized and 28.5% having asthma.Conclusion: Using model‐based clustering, we identified several distinct patterns of cytokine response to HDM and observed interplay between cytokine expression level, cytokine patterns (especially IL‐13 and IL‐5), and clinical outcomes. ‘IL‐13 and IL‐5 high responders’ class was strongly associated with HDM sensitization. However, among HDM‐sensitized children, one‐third showed no PBMC response to HDM, and the majority of HDM‐sensitized children did not have asthma or wheeze. Our findings suggest that positive HDM ‘allergy tests’ and asthma are associated with a broad range of immunophenotypes, which may have important implications for the use of cytokine‐targeted treatment approaches.


  • Interaction between glutathione S‐transferase variants, maternal smoking and childhood wheezing changes with age

    by Jiakai Wu, Jenny Hankinson, Kamilla Kopec‐Harding, Adnan Custovic, Angela Simpson

    Maternal smoking increases the risk of respiratory symptoms in children. Glutathione S-transferases (GSTs) detoxify xenobiotics from tobacco smoke, and functional polymorphism in GST gene(s) could predispose children to the detrimental effects of maternal smoking. Our objective was to investigate interactions between GST variants and maternal smoking in relation to the development of wheezing during childhood and whether any such interaction changes with time. In a population-based birth cohort, we assessed maternal smoking and current wheeze at five time points during the first 11 yr of life. DNA was genotyped for GSTP1, GSTM1 and GSTT1 (n = 807). Longitudinal analyses were performed using generalized estimating equations. During early childhood, children whose mothers smoked were more likely to wheeze, with the strongest association observed at age 3 yr (p = 0.006). In a longitudinal model, children with GSTP1 AA and AG genotypes had significantly higher risk of wheeze compared with GG homozygotes. We observed a significant interaction between GSTP1 and maternal smoking where the risk of infantile wheezing was significantly increased in AA homozygotes, but only if their mothers smoked (OR 2.59, [1.08-6.21], p(int) = 0.03). Furthermore, amongst AA carriers, there was a significant interaction between child's age and maternal smoking, with the effect of maternal smoking on the risk of wheeze significantly diminishing with age (p(int) = 0.05); no such findings were observed for GSTM1 and GSTT1. Children with AA genotype for GSTP1 are at increased risk of early-life wheezing if their mothers smoke, but the effect of maternal smoking on wheezing diminishes with time.